Registration
A protocol entry can establish that a study was planned or registered. It does not establish completion, accurate enrollment, or a clinical result.
Evidence status · late 2026
Trials Landscape
A cautious guide to the known human evidence, trial registrations, and reported cohorts involving ibogaine and Parkinson’s disease—organized around what can be verified, what remains uncertain, and what cannot yet support a treatment conclusion.
For broader orientation on experimental ibogaine questions, the independent research overview provides the wider context for separating early hypotheses from established care. Parkinson’s disease is a complex neurological condition, and the National Institute of Neurological Disorders and Stroke overview of Parkinson’s disease describes it as a progressive disorder with diverse motor and non-motor features.
Important: this page does not identify ibogaine as an established Parkinson’s treatment. It is an evidence-focused record of a limited and unsettled landscape.
- Human evidence separated from preclinical work
- Registrations checked as public records
- Clinic accounts not treated as proof
- Safety uncertainty kept visible
The record to date
What is documented—and what is not
This topic is often discussed through personal accounts, informal clinic descriptions, or extrapolation from laboratory research. Those sources are not interchangeable with completed, peer-reviewed clinical trials in Parkinson’s disease.
As of late 2026, this guide does not identify a completed, peer-reviewed randomized clinical trial testing ibogaine for Parkinson’s disease. It also does not identify a verified peer-reviewed human case report that can establish an effect on Parkinson’s symptoms, progression, or quality of life. Absence from this landscape is not proof that no account exists; it means an account should not be represented as a completed clinical evidence base without a citable primary record.
A note on bibliographic citations
No completed Parkinson’s-specific ibogaine study is listed here with a bibliographic citation because no verified citation meeting that description has been identified. Naming an unverified paper, trial, sample size, endpoint, sponsor, location, or registry identifier would create false precision.
Ibogaine is most commonly discussed in connection with substance-use treatment claims, a context that should not be transferred to Parkinson’s disease. Questions raised by ibogaine for opioid addiction involve a different population, indication, risk profile, and research history. Likewise, speculative neurological comparisons should be kept distinct from the evidence reviewed in material about ibogaine and brain injury.
- Completed Parkinson’s-specific clinical trials No verified completed trial was identified for inclusion in this evidence map as of late 2026.
- Peer-reviewed Parkinson’s-specific human case reports No verified case report was identified for inclusion as evidence of efficacy or safety in Parkinson’s disease.
- Preclinical and hypothesis-generating work Laboratory, animal, mechanistic, or non-Parkinson’s observations may generate questions but do not answer whether ibogaine is safe or effective for people with Parkinson’s disease.
Registry check
Ongoing or planned trials
A public registry can show that a study was proposed, opened, recruiting, suspended, completed, or withdrawn. It cannot by itself show that an intervention worked. For this reason, registry IDs, sponsor names, locations, participant counts, status labels, and endpoints should only be reported when they can be verified directly in the source record.
As of late 2026, this guide does not identify a verified Parkinson’s-specific ibogaine registration with sufficient public documentation to list a registry ID, site location, sponsor, recruitment status, or protocol endpoint. Readers can independently repeat the search in ClinicalTrials.gov’s public study database, using both “ibogaine” and “Parkinson disease” and then checking each result’s full record.
When a registration is found, the useful questions are straightforward: Is Parkinson’s disease the studied condition? Is ibogaine actually the intervention? Is the record current? What are the primary outcomes, planned enrollment, study design, exclusion criteria, and safety-monitoring provisions? The trial-design guide explains why those details matter before any headline or anecdote is interpreted as a result.
Completion
A completed status still needs a results record or primary publication before outcomes can be assessed in context.
Publication
Even a published report must be read for design, sample size, comparison group, endpoints, follow-up, missing data, and adverse events.
Reported settings are not trial sites
Clinic-reported cohorts require a separate category
Some claims may arise from treatment settings rather than registered academic or hospital-based research. A clinic-reported cohort can be relevant as a lead for further investigation, but it is not equivalent to a peer-reviewed case report or controlled clinical study. Without a prespecified protocol, independently collected outcomes, complete accounting of participants, and systematic adverse-event reporting, it cannot establish efficacy or safety.
Colorado references
Material about ibogaine treatment in Colorado should not be read as evidence of a Parkinson’s-specific trial unless a verifiable study record says so.
Mexico references
Accounts involving ibogaine treatment settings in Mexico likewise need a public protocol and transparent outcomes before they can be treated as research evidence.
Cost references
Information about ibogaine retreat costs is not a measure of study quality, medical oversight, or evidence for Parkinson’s disease.
How to weigh a claim
Methodological limits are part of the result
A small observation can be meaningful to the person describing it, but it cannot answer the same question as a controlled clinical study. The gap is especially important where symptoms fluctuate, expectations are high, and risks may be serious.
For Parkinson’s disease, an adequate study would need to define who was enrolled, how the diagnosis was confirmed, what other medications or treatments were used, how outcomes were measured, how long participants were followed, and how serious adverse events were captured. It would also need to address comparison conditions and the possibility that expectancy, natural variation, or concurrent care could influence reports.
Ibogaine itself has substantial safety concerns. The U.S. Food and Drug Administration’s official ibogaine information page notes that ibogaine is not approved for medical use in the United States and describes serious risks, including cardiac concerns. A Parkinson’s diagnosis does not remove those concerns, and individual risk assessment belongs with qualified medical professionals who know a person’s health history and medicines.
The word “clinical trial” has a specific meaning: a prospectively organized study in people designed to answer a defined health question. The clinical trial definition and history can be useful background, but the key practical distinction is simple: a personal account, a treatment promotion, or an informal collection of experiences is not automatically a trial.
Plain-language bottom line An uncontrolled series cannot tell readers whether a change was caused by ibogaine, how often harms occurred, whether results would persist, or how outcomes would compare with usual care or another intervention.
A repeatable check
How to verify future updates
New claims should be traced back to the source before they are repeated. Start with the registry record, then look for a peer-reviewed paper that matches the same study population, intervention, dates, enrollment, and stated outcomes. If a paper is unavailable, avoid filling the gap with promotional summaries or secondhand commentary.
-
Search the registries
Look for “ibogaine” and “Parkinson disease,” review the full record, and preserve the registry ID only after the condition and intervention match.
-
Locate the primary report
Compare the publication with the record’s design, population, endpoints, enrollment, status, and dates. A registry entry and a completed paper should describe the same study.
-
Check safety reporting
Read beyond symptom claims for exclusions, deaths, serious adverse events, discontinuations, interactions, and the length of follow-up.
-
Keep categories intact
Label peer-reviewed reports, uncontrolled clinic descriptions, personal narratives, and preclinical work separately rather than combining them into one evidence claim.
For ongoing monitoring, readers may compare claims with ibogaine developments discussed publicly, but a primary registry or paper should remain the deciding record. First-person narratives such as an ibogaine trip account may describe an individual experience; they cannot substitute for systematic Parkinson’s research.
Common questions
Questions this landscape can answer
This guide is designed to make the evidence boundary visible rather than to convert uncertainty into a recommendation.
Does a clinic-reported cohort establish that ibogaine works for Parkinson’s disease?
No. A clinic-reported cohort may describe experiences or observations, but without a prespecified protocol, appropriate comparison group, independently collected outcomes, and complete adverse-event reporting, it cannot establish efficacy or safety. The broader safety and risk context is essential before any claim is interpreted.
Where can a reader verify whether a registered trial exists?
Search the public ClinicalTrials.gov database using ibogaine and Parkinson disease, then compare any record with its sponsor, recruitment status, dates, eligibility criteria, outcomes, and linked publications. A registry search should be repeated periodically because records can be added or updated.
Why does trial design matter so much for Parkinson’s claims?
Parkinson’s symptoms can vary over time, outcomes may be influenced by expectation and concurrent care, and short-term reports cannot answer questions about durability, harms, or effects on disease progression. A prespecified, controlled design is needed to interpret results.
Dated changelog
Update record
Late 2026: Initial landscape published. No verified completed Parkinson’s-specific ibogaine clinical trial, peer-reviewed Parkinson’s-specific human case report, or sufficiently documented Parkinson’s-specific registry record was identified for listing with a bibliographic citation, trial ID, location, sponsor, or status.
Future entries should identify the date checked, name the primary source, state the evidence category, and describe design and limitations without converting preliminary findings into treatment claims. For questions about the site’s approach to evidence and independence, see our stated evidence principles